iBio, Inc. Common Stock Earnings

The next earnings date for iBio, Inc. Common Stock has not yet been scheduled.

Analyst Estimates of iBio, Inc. Common Stock Earnings

No Results.

Report Date	Estimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

iBio, Inc. Common Stock Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
05/12/2025	Before Market	$-0.49	-53.13%
02/07/2025	After Market	$-0.48	---
11/12/2024	After Market	$-0.46	3.73%
09/25/2024	After Market	$-0.90	-91.89%
05/13/2024	After Market	$-0.85	---
02/09/2024	After Market	$-4.42	---
11/13/2023	After Market	$-0.24	---
09/27/2023	After Market	$0.26	163.41%
05/15/2023	Before Market	$-0.55	-53.67%
02/14/2023	After Market	$-1.08	-74.19%
10/11/2022	After Market	$-1.96	7.55%
09/27/2022	After Market	$-1.96	7.55%
05/12/2022	After Market	$-1.50	-9.49%
02/14/2022	After Market	$-1.25	-25.00%
11/15/2021	After Market	$-1	20.00%
09/27/2021	Before Market	$0.01	125.00%
05/17/2021	Before Market	$-1	20.00%
02/16/2021	After Market	$-1	0.00%
10/13/2020	After Market	$-1.25	0.00%
05/15/2020	After Market	$-0.06	---
02/14/2020	Before Market	$-0.69	---
11/14/2019	After Market	$-0.21	---
08/26/2019	After Market	$-0.23	---
05/10/2019	After Market	$-0.22	---
02/13/2019	After Market	$-0.24	---
11/13/2018	After Market	$-0.25	---
09/18/2018	After Market	$-0.38	---
05/11/2018	After Market	$-0.35	---
02/15/2018	Before Market	$-0.41	---
11/09/2017	After Market	$-0.42	---
09/15/2017	After Market	$-0.49	---
05/15/2017	After Market	$-0.44	---
02/21/2017	After Market	$-0.36	---
10/13/2016	After Market	$-0.34	---
08/31/2016	---	$-150.21	---
06/01/2016	---	$-187.04	---
03/02/2016	---	$-145.23	---
12/02/2015	---	$-116.74	---
09/02/2015	---	$-100	---
06/03/2015	---	$-114.88	---
02/25/2015	---	$-116.48	---
12/03/2014	---	$-107.05	---
09/03/2014	---	$-86.99	---
05/28/2014	---	$-97.42	---
02/26/2014	---	$-126.98	---
11/27/2013	---	$31.26	---
05/29/2013	---	$-184.01	---
02/27/2013	---	$-112.12	---
10/12/2012	---	$-5	77.78%
08/29/2012	---	$-172.45	---
05/15/2012	---	$-17.50	-7.69%
02/29/2012	---	$-246.69	---
11/14/2011	---	$2.50	114.29%
09/29/2011	---	$-10	42.86%
05/18/2011	---	$-22.50	-125.00%
02/14/2011	---	$-37.50	-275.00%
11/15/2010	---	$-25	-233.33%
09/01/2010	---	$-472.97	---
05/19/2010	---	$-15	-200.00%
02/16/2010	---	$-2.50	90.00%

More About iBio, Inc. Common Stock

Website

https://ibioinc.com

Country

USA

Full Time Employees

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

“iBio, Inc. Common Stock Earnings” Can Refer to the iBio, Inc. Common Stock Earnings Date

Some people say “iBio, Inc. Common Stock earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my iBio, Inc. Common Stock position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning iBio, Inc. Common Stock Stock on the Earnings Date

If you own iBio, Inc. Common Stock stock (IBIO) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for iBio, Inc. Common Stock might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading iBio, Inc. Common Stock shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More iBio, Inc. Common Stock Earnings

You can contact us any time if you would like to ask questions about iBio, Inc. Common Stock earnings or anything else related to the stock market.